Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GW842470X cream
GW842470X · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Single dose 1 cohort | EXPERIMENTAL | Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1. |
| Repeat dose 1 cohort | EXPERIMENTAL | Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1 |
| Repeat dose 2 cohort | EXPERIMENTAL | Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1 |
| Repeat dose 3 cohort | EXPERIMENTAL | Subjects with BSA disease involvement \>=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1 |
| Name | Type | Description |
|---|---|---|
| GW842470X cream | DRUG | - |
| GW842470X | DRUG | GW842470X will be available as a yellow smooth water-in-oil cream. |
| Placebo | DRUG | GW842470X matching placebo will be available as a yellow smooth water-in-oil cream. |
Inclusion criteria: * Moderate atopic dermatitis patients (IGA=3). * The disease involvement must be \>5% of body surface area. * Female patients of child-bearing potential must use an appropriate method of contraception. Exclusion criteria: * Patients with any active skin disease other than atop...
Top 20 of 26 competitors
GW842470X is an investigational small molecule drug developed by GSK plc for atopic dermatitis, a form of eczema. It is formulated as a topical cream and was studied in clinical trials in adult patients with moderate atopic dermatitis. It is not approved and remains in clinical development.
GW842470X is being studied for the treatment of atopic dermatitis, also called atopic eczema. The clinical program focused on adults with moderate atopic dermatitis, evaluating topical application of the cream. It is an investigational therapy and has not been approved for any indication.
GW842470X is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the clinical trials of the topical cream in patients with atopic dermatitis.
GW842470X has completed Phase 2 clinical development for atopic dermatitis. Two trials have been completed, one Phase 1 study and one Phase 2 study, and no trials are currently active. The drug is investigational and has not been approved by the FDA.
GW842470X has been evaluated in two completed trials. NCT00356642 was a Phase 1 study of single and ten day repeat topical applications in 45 patients with atopic dermatitis in Germany. NCT00354510 was a Phase 2 trial of topical GW842470X in 190 adults with moderate atopic dermatitis in Germany and the Netherlands.
Yes, GW842470X cream is the same asset as GW842470X. The cream refers to the topical formulation used in the clinical trials, which applied the drug directly to the skin of patients with atopic dermatitis. Both names refer to the GSK investigational compound.